title: FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.
abstract: The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.
authors.affiliation: National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, Pennsylvania, USA. saima.sharif@nsabp.org
authors.forename: Saima
authors.initials: S
authors.lastname: Sharif
authors.forename: Michael J
authors.initials: MJ
authors.lastname: O'Connell
authors.forename: Greg
authors.initials: G
authors.lastname: Yothers
authors.forename: Samia
authors.initials: S
authors.lastname: Lopa
authors.forename: Norman
authors.initials: N
authors.lastname: Wolmark
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil
references.citation: J Clin Oncol. 2000 Aug;18(16):2938-47
references.pmid: 10944126
references.citation: J Clin Oncol. 1993 Oct;11(10):1879-87
references.pmid: 8410113
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2205-11
references.pmid: 17470850
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: Cancer. 2007 Nov 1;110(9):1945-50
references.pmid: 17853393
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: J Clin Oncol. 1997 Feb;15(2):808-15
references.pmid: 9053508
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8664-70
references.pmid: 16260700
references.citation: Lancet. 2000 Mar 25;355(9209):1041-7
references.pmid: 10744089
references.citation: J Clin Oncol. 2004 Jan 1;22(1):23-30
references.pmid: 14665611
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2198-204
references.pmid: 17470851
references.citation: Adv Exp Med Biol. 1988;244:143-55
references.pmid: 3073651